Special Issue "Psychoactive Substances in Disease Treatment: Trends and Developments"
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: 31 July 2023 | Viewed by 192
Special Issue Editors
2. Pharmaco-Toxicology Laboratory, UBIMedical, University of Beira Interior, Covilhã, Portugal
Interests: toxicology; analytical method development; recreational drugs; natural psychoactive substances; therapeutic drug monitoring; sample preparation; alternative samples; miniaturized extraction procedures
2. Laboratório de Farmaco-Toxicologia, UBIMedical, Universidade da Beira Interior (CICS-UBI), 6201-506 Covilhã, Portugal
Interests: toxicology; analytical method development; recreational drugs; natural psychoactive substances; therapeutic drug monitoring; sample preparation; alternative samples; miniaturized extraction procedures
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Many new psychoactive substances are close relatives or analogues of drugs that were first discovered by the pharmaceutical sector. Although psychoactive substances are still discussed as potentially harmful illegal substances for recreational purposes, they have also been researched as potential medicines. Numerous studies suggest that substances such as ketamine and 3,4-methylenedioxymethamphetamine (MDMA) are promising therapeutic approaches in contemporary psychiatry. Their efficacy for treating depression, nicotine and alcohol addictions, as well as psychological distress associated with life-threatening diseases, has been noteworthy.
Additionally, psychoactive substances of natural origin have demonstrated therapeutic potential. Compounds such as dimethyltryptamine (DMT)—present in ayahuasca, psilocybin from magic mushrooms, lysergic acid diethylamide (LSD) and cannabis—are promising medicines to treat neurological and psychiatric disorders.
As psychoactive substance therapy may become a legitimate medical choice, its distribution and acceptability by mental health care professionals may be hampered by its stigma. Redefining psychotherapy procedures and placing psychopharmacological therapies inside a new treatment infrastructure may be required.
With this Special Issue, we welcome both original research or review articles that will focus on the use of psychoactive substances as therapeutics and/or their implications.
Dr. Tiago Rosado
Prof. Dr. Eugenia Gallardo
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- psychoactive substances
- recreational drugs
- natural products
- therapeutic potential
- disease treatment
- psychopharmacology therapy
Planned Papers
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Many new psychoactive substances are close relatives or analogues of drugs that were first discovered by the pharmaceutical sector. Although psychoactive substances are still discussed as potentially harmful illegal substances for recreational purposes, they have also been researched as potential medicines. Such as ketamine and 3,4-methylenedioxymethamphetamine (MDMA) are promising therapeutic approaches in contemporary psychiatry.
Additionally, psychoactive substances of natural origin have demonstrated therapeutic potential. Compounds such as dimethyltryptamine (DMT)—present in ayahuasca, psilocybin from magic mushrooms, lysergic acid diethylamide (LSD).
As psychoactive substance therapy may become a legitimate medical choice, its distribution and acceptability by mental health care professionals may be hampered by its stigma. Redefining psychotherapy procedures and placing psychopharmacological therapies inside a new treatment infrastructure may be required.
With this Special Issue, we welcome both original research or review articles that will focus on the use of psychoactive substances as therapeutics and/or their implications.
